Investigation of the therapeutic interaction of mesenchymal stem cells with glioblastoma stem-like cells and its biological mechanism
Project/Area Number |
16K19996
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Neurosurgery
|
Research Institution | Kanazawa University |
Principal Investigator |
Pyko Ilya 金沢大学, がん進展制御研究所, 博士研究員 (00731853)
|
Project Period (FY) |
2016-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | glioblastoma / temozolomide / mesenchymal stem cells / GSK3β / GSK 3β |
Outline of Final Research Achievements |
We investigated whether mesenchymal stem cells (MSCs) transplantation benefits to treatment of glioblastoma (GBM) by enhancing anti-tumor effect in combination with GSK3β inhibitors and temozolomide (TMZ). We showed that MSCs co-cultured with GBM cells participate in regulation of GBM stem-like cell (SC) morphology. We examined the interaction between patient-derived GBM-SCs and adipose tissue-derived MSCs under GSK3β inhibition and TMZ and its influence on GBM-SCs. We found that combined treatment by GSK3β inhibitor enhanced therapeutic interaction of MSCs with GBM-SCs, and that combination of low-dose AR-A014418, TMZ and MSC treatment significantly reduced cell viability and showed anti-tumor effect against patient-derived GBM-SCs. Transplantation of MSCs and GSK3β inhibition improved survival in mouse GBM model.
|
Report
(3 results)
Research Products
(10 results)